- Home
- RXO vs OGN Comparison
RXO vs OGN Comparison
Compare RXO & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RXO
- OGN
- Stock Information
- Founded
- RXO 2022
- OGN 1923
- Country
- RXO United States
- OGN United States
- Employees
- RXO N/A
- OGN N/A
- Industry
- RXO
- OGN Biotechnology: Pharmaceutical Preparations
- Sector
- RXO
- OGN Health Care
- Exchange
- RXO Nasdaq
- OGN Nasdaq
- Market Cap
- RXO 2.6B
- OGN 2.7B
- IPO Year
- RXO N/A
- OGN N/A
- Fundamental
- Price
- RXO $17.41
- OGN $6.34
- Analyst Decision
- RXO Hold
- OGN Buy
- Analyst Count
- RXO 15
- OGN 3
- Target Price
- RXO $18.08
- OGN $17.33
- AVG Volume (30 Days)
- RXO 1.7M
- OGN 6.3M
- Earning Date
- RXO 11-06-2025
- OGN 10-30-2025
- Dividend Yield
- RXO N/A
- OGN 1.20%
- EPS Growth
- RXO N/A
- OGN N/A
- EPS
- RXO N/A
- OGN 2.69
- Revenue
- RXO $5,559,000,000.00
- OGN $6,281,000,000.00
- Revenue This Year
- RXO $29.34
- OGN N/A
- Revenue Next Year
- RXO $7.07
- OGN $0.65
- P/E Ratio
- RXO N/A
- OGN $2.36
- Revenue Growth
- RXO 46.41
- OGN N/A
- 52 Week Low
- RXO $12.19
- OGN $6.32
- 52 Week High
- RXO $31.98
- OGN $19.05
- Technical
- Relative Strength Index (RSI)
- RXO 52.34
- OGN 15.64
- Support Level
- RXO $16.80
- OGN $8.87
- Resistance Level
- RXO $17.95
- OGN $9.28
- Average True Range (ATR)
- RXO 0.89
- OGN 0.35
- MACD
- RXO -0.04
- OGN -0.35
- Stochastic Oscillator
- RXO 52.42
- OGN 0.56
About RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About OGN Organon & Co.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.